Effector Therapeutics Stock Price To Earning
Effector Therapeutics fundamentals help investors to digest information that contributes to Effector Therapeutics' financial success or failures. It also enables traders to predict the movement of Effector Stock. The fundamental analysis module provides a way to measure Effector Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Effector Therapeutics stock.
Effector |
Effector Therapeutics Company Price To Earning Analysis
Effector Therapeutics' Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Current Effector Therapeutics Price To Earning | 1.03 X |
Most of Effector Therapeutics' fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Effector Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
CompetitionBased on the latest financial disclosure, Effector Therapeutics has a Price To Earning of 1.03 times. This is 96.01% lower than that of the Biotechnology sector and 79.11% lower than that of the Health Care industry. The price to earning for all United States stocks is 96.41% higher than that of the company.
Did you try this?
Run Portfolio Analyzer Now
Portfolio AnalyzerPortfolio analysis module that provides access to portfolio diagnostics and optimization engine |
All Next | Launch Module |
Effector Fundamentals
Return On Equity | -9.47 | ||||
Return On Asset | -0.83 | ||||
Current Valuation | (4.52 M) | ||||
Shares Outstanding | 4.7 M | ||||
Shares Owned By Insiders | 2.90 % | ||||
Shares Owned By Institutions | 23.71 % | ||||
Number Of Shares Shorted | 91.62 K | ||||
Price To Earning | 1.03 X | ||||
Price To Book | 13.38 X | ||||
Price To Sales | 69.65 X | ||||
Gross Profit | (19.76 M) | ||||
EBITDA | (33.73 M) | ||||
Net Income | (35.81 M) | ||||
Cash And Equivalents | 41.04 M | ||||
Cash Per Share | 0.99 X | ||||
Total Debt | 19.45 M | ||||
Debt To Equity | 1.03 % | ||||
Current Ratio | 1.79 X | ||||
Book Value Per Share | 0.21 X | ||||
Cash Flow From Operations | (29.55 M) | ||||
Short Ratio | 0.97 X | ||||
Earnings Per Share | (12.57) X | ||||
Target Price | 11.0 | ||||
Number Of Employees | 14 | ||||
Beta | 0.83 | ||||
Market Capitalization | 846.79 K | ||||
Total Asset | 20.54 M | ||||
Retained Earnings | (179.38 M) | ||||
Working Capital | (5.96 M) | ||||
Net Asset | 20.54 M |
Pair Trading with Effector Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Effector Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Effector Therapeutics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Peabody Energy could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Peabody Energy when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Peabody Energy - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Peabody Energy Corp to buy it.
The correlation of Peabody Energy is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Peabody Energy moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Peabody Energy Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Peabody Energy can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Other Consideration for investing in Effector Stock
If you are still planning to invest in Effector Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Effector Therapeutics' history and understand the potential risks before investing.
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |